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Abstract
As medical advances lengthen average life expectancy, osteoarthritis (OA) will become a larger public
health problem – not only because it is a manifestation of aging but also because it usually takes many
years to reach clinical relevance. OA is already one of the ten most disabling diseases in industrialized
countries. The huge financial burden emphasizes the acute need for new and more effective
treatments for articular cartilage defects, especially since there are few disease modifying drugs or
treatments for OA. There is no cure for OA and the management of OA is largely palliative, focusing
on the alleviation of symptoms. Recent longitudinal non-controlled trials suggest that autologous
chondrocyte transplantation techniques, which are indicated for young people with traumatic
cartilage defects, could also be used in degenerative defects of elderly people with OA. This report
discusses this therapeutic opportunity in view of some recently published data.
Introduction and context
In adults, damaged cartilage has a very limited capacity
for self-healing due to the absence of blood vessels, the
low intrinsic density of chondrocytes, and the low
turnover of the extracellular matrix [1]. The absence of
stem cells and the low capacity of resident chondrocytes
to migrate and proliferate also reduce cartilage regenera-
tion capacity. Therefore, numerous methods have been
proposed to repair cartilage defects in young or
osteoarthritis (OA) subjects [2]. Intrinsic repair can be
stimulated by bleeding induced by drilling or micro-
fracturing the subchondral bone. Fibrin clot formation,
vascular invasion, and recruitment of stem cells into the
defect result in the formation of scar tissue that is inferior
biomechanically to normal cartilage and susceptible,
therefore, to degeneration.
In osteochondral transplantation (or mosaicplasty),
osteochondral plugs are transferred from undamaged
and relatively non-weight-bearing regions to a debrided
site. However, studies have shown that this technique
results in donor site morbidity and extensive chondro-
cyte death in the margins of the osteochondral plugs.
One option to treat focal cartilage lesions is autologous
chondrocyte implantation (ACI), a procedure developed
in the late 1980s to treat traumatic and symptomatic
cartilage lesions in the knees of young adults. The idea
behind the ACI procedure is to take a cartilage biopsy
from the knee by arthroscopy, to isolate cells and grow
them in the lab and, once millions of cells have been
grown, to implant them into the area of cartilage damage
beneath a periosteal flap or a collagen sheet sutured to
the surrounding healthy cartilage rim.
More recently, matrix-assisted autologous chondrocyte
implantation (MACI) has been proposed as an alter-
native to ACI. This technique uses a biomaterial as a
chondrocyte carrier that is directly implanted in the
lesion [3-5]. The matrix can be synthetic, including but
not limited to poly(lactic acid), poly(glycolic acid),
poly(lactic-co-glycolic acid) copolymer, poly(ethylene
oxide), or poly(propylene oxide) polymers that all gel at
body temperature, ceramic composite and hydrogel-
containing polyethylene glycol polymer-based deriva-
tives [6], or natural substances such as fibrin, collagens,
alginate, agarose, chitosan, and hyaluronic acid. These
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scaffolds in a rich variety of configurations, including
woven and non-woven meshes [7], sponges, foam, glues
[8], bilayer or trilayer composites [9] and, more recently,
small-size magnetic beads [10,11]. To promote chon-
drogenesis (differentiation to chondrocyte-like cells) and
scaffold integration, many MACI systems using growth
factors, either attached to the scaffolds or through
recombinant expression, have been proposed [12].
Several studies have also shown that pulsed electro-
magnetic field and continuous passive motion may
promote chondrogenesis and implant integration to the
existing cartilage [13]. Until now, ACI/MACI techniques
have been reserved for patients who meet the following
criteria [14]: age 15-60 years; body mass index (BMI)
≤35;presenceofdisablingpainand/orkneelocking;focal
articular cartilage defect down to but not through the
subchondral bone on a load bearing surface of the
femoral condyle (medial, lateral, trochlear) (not in
the patella); size of defect <7 mm in depth, <6 cm in
length, and 1.6-10 cm
2 in area; stable knee with intact
meniscus and normal joint space on X-ray; no active
inflammatory or other arthritis, clinically and by
X-ray; procedure is not being done for treatment of
degenerative arthritis (OA); failure of conservative
therapy (minimum of 2 months of physical therapy) as
well as established surgical interventions (i.e., micro-
fracture, drilling, abrasion) – diagnostic arthroscopy,
lavage, or debridement are not considered adequate to
meet this criterion; cooperation with post-operative
weight-bearing restrictions and activity restrictions
together with a potential for completion of post-
operative rehabilitation; and informed consent with
realistic expectations.
Recent advances
Currently, ACI is contraindicated in OA because the risks
of complications and failure are high and clinical
superiority has not been demonstrated compared with
other treatments. In young adults with traumatic
chondral lesions, re-operation is a common sequel of
ACI with an incidence of 15-30% [15,16]. Periosteal
hypertrophy and delamination, which account for
22.1% and 17.7%, respectively, of adverse effects
reported to the US Food and Drug Administration,
frequently require ACI site debridement [17]. Failure of
ACI occurs in 4-22% of patients depending on defect
traits and duration of follow-up [18]. The rate of failure
increases with time from surgery and age. A study of
single condylar defects reported 5% failure at 2 years,
which increased to 22.5% at 5 years. One comparison of
ACI by patient age demonstrated good to excellent
results in 85.7% of patients younger than 20 years
compared with 55.9% in those older than 40 years [19].
Recently, an extensive case report has shown that MACI
based on a bioresorbable two-component gel-polymer
scaffold is effective for the treatment of focal degenera-
tive cartilage defects of the knee in subjects between 25
and 50 years of age [20]. This product is composed of
fibrin and a polymer-based scaffold of polyglycolic/
polylactic acid (polyglactin, vicryl) and polydioxanone.
In this study, 18 patients with preoperatively radiologi-
cally confirmed OA and a Kellgren-Lawrence score of 2 or
more were included and followed up for 4 years. The
average age of patients (8 females and 10 males) was
35 years (25-50 years), the mean BMI was 25 (ranging
from19to24)andmeandefectsizewas4cm
2(2-6cm
2).
Two patients had to undergo surgery and received a total
knee prosthesis. Clinical improvement has been assessed
by different scoring systems, including the Lysholm and
International Cartilage Repair Society (ICRS) scores and
the Knee injury and Osteoarthritis Outcome Score
(KOOS). After 1 year, mean scores improved between
30% and 50% compared with the pre-operative situa-
tion, depending on which score was analyzed. The
clinical results 1 year after implantation of the scaffold
were good and remained stable for at least 4 years. This
indicates a significant decrease in pain and disability as
well as a significant increase in quality of life. However,
nine patients were subjected to second-look arthroscopy
due to symptoms such as persistent grinding, catching
pain, or swelling. Magnetic resonance imaging per-
formed 4 years after transplantation in 17 patients
showed a complete filling of the defect with cartilage
repair tissue in 11 patients. In five patients, the defects
were filled more than 50% and one patient showed a
defect fill of less than 50%. The cartilage signal in 16 out
of 17 defects was normal or showed a slight alteration of
the signal. Strong to moderate subchondral edema was
evident in 6 patients, and 11 out of 17 patients showed
no or mild edema. Five patients showed moderate to
strong signs of knee joint effusion. No to mild knee joint
effusion was evident in 12 out of 17 patients treated at
4-year follow-up. These results are promising but need to
be reproduced in older patients with chondrocytes
affected by the aging processes.
In a retrospective study by Minas et al. [21], 56 patients
≥45 years of age were treated with ACI using periosteal
flap. The mean transplant size was 4.7 cm
2 per defect
(range, 1-15 cm
2) and 9.8 cm
2 per knee (range, 2.5-
31.6 cm
2). There were eight failures (14%), mainly in
patients receiving workers’ compensation, and 24 addi-
tional arthroscopic surgical procedures for periosteal-
related problems and adhesion. At their latest available
follow-up, 72% of patients rated themselves as good or
excellent, and 78% felt improved and would again
choose ACI as a treatment option.
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Implications for clinical practice
These studies, even if they are limited to prospective or
retrospective non-controlled trials, suggest that ACI/
MACI systems could be used to prevent or delay total
joint replacement in OA. Is this goal utopian or a real
opportunity? These repair techniques are invasive,
associated with some complications (locking of the
joint and adhesions, extension deficit, recurrent knee
effusion, and so on) and have an approximately 10% risk
of failure. ACI/MACI show great promise as treatments
for chondral lesions, with a potential for them to be
highly cost effective. But at present this has not been
demonstrated and recommendation of this technique for
the treatment of cartilage defects in OA joint can not yet
be justified. The superiority of ACI/MACI compared with
other OA treatments, such as hyaluronic acid injection or
other surgical procedures (debridement, microfractures),
needstobedemonstrated.Further,thesemethodsrequire
a complex process of tissue harvest, cell culture, scaffold
implantation and finally post-operative rehabilitation.
What are the clinical benefits that justify this investment
in OA? Promising developments are underway with
regards to cell-based techniques in combination with
scaffolds, growth factors, and gene therapy. Unfortu-
nately, this effort has not been followed by appropriate
or sufficient clinical studies to assess these new methods
and to compare them with existing systems. Further
research is needed to simplify the implantation proce-
dure and to improve the success level. OA patients are
generally older and heavier than the population included
in the current studies and we lack data on the incidence
of failure in this population. Altogether, the use of ACI or
MACI techniques in OA patients remains experimental
but constitutes a real opportunity for such patients in the
next decade. The main problems still to be resolved are
how to produce a hyaline cartilage rather than a
fibrocartilage, how to facilitate the integration of the
repair within the surrounding tissue,and how to simplify
the implementation procedure.
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